In this article, we break down the Top 5 Small-Cap Biotech Stocks With Billion-Dollar Upside Potential. For investors looking for the complete list, you can explore our full report on the Top 10 Small-Cap Biotech Stocks With Billion-Dollar Upside Potential.
5. Innoviva Inc. (NASDAQ:INVA)
Innoviva ranks No. 5 because it offers something many small-cap biotech companies cannot provide: actual revenue, royalty economics, product sales, and a business model that is not entirely dependent on one upcoming clinical readout. In a sector full of cash-burning companies waiting for trial results, INVA stands out because it has a royalty foundation and a specialty therapeutics business, particularly in critical care and infectious disease. That makes it one of the more financially grounded names on this list.
In its first-quarter 2026 results, Innoviva reported royalty and net product sales receivables of $92.6 million as of March 31, 2026, while also highlighting progress in its business and R&D activities. The company’s earlier 2025 performance also showed the strength of its platform, with management noting 15% revenue growth to more than $400 million, net income above $270 million, a royalty business that continued to provide stable cash flow, and strong year-over-year U.S. sales growth from Innoviva Specialty Therapeutics.
That financial base is why INVA deserves a middle-to-upper ranking. It may not have the same dramatic clinical upside as a pure cancer or gene-editing stock, but it has a stronger foundation. For readers searching for small-cap healthcare stocks, profitable biotech stocks, or biopharma stocks with revenue, Innoviva is a more sober but still interesting candidate. The tradeoff is that its upside may look less explosive than a clinical-stage company that could double on strong trial results. But in risk-adjusted terms, INVA deserves respect because it has operating substance, not just laboratory promise.
Click next to see the following stock...
